Printer Friendly

THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMIT $18 MILLION ADDITIONAL FUNDING FOR AIDS JOINT VENTURE

 THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC.
 COMMIT $18 MILLION ADDITIONAL FUNDING FOR AIDS JOINT VENTURE
 SAN DIEGO and COLLEGEVILLE, Pa., May 14 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) and Rhone-Poulenc Rorer Inc. (NYSE: RPR) announced today that the companies have agreed to invest an additional $9 million each in their AIDS joint venture, Immunization Products Ltd. The joint venture is developing an HIV therapeutic vaccine, currently in a Phase II/III nationwide clinical trial as a treatment for HIV-infected patients. Following payment of the new commitment, the partners will have contributed a total of $36 million in capital to the joint venture.
 The new investment in the joint venture continues the commitment by both Immune Response and Rhone-Poulenc Rorer to the development of the HIV therapeutic vaccine. Immune Response and Rhone-Poulenc Rorer expect the additional $18 million to support the ongoing Phase II/III clinical trial, additional planned clinical trials and expenses related to the potential commercialization of the HIV therapeutic vaccine. The newly committed capital investments are expected to be made in several installments during 1992 and 1993. The joint venture may need additional capital beyond this $18 million commitment to support the development of the HIV therapeutic vaccine.
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection, which leads to AIDS, and for the treatment of certain autoimmune diseases, particularly rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes.
 Rhone-Poulenc Rorer Inc. is a global pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of human pharmaceuticals. RPR has annual sales of $3.8 billion and research expenditures of more than $440 million. The company operates in all major markets of the world.
 -0- 5/14/92
 /CONTACT: Steven Basta of The Immune Response Corporation, 619-431-7080; or Jane Green of Rhone-Poulenc Rorer, 215-454-3871/
 (IMNR RPR) CO: The Immune Response Corporation; Rhone-Poulenc Rorer Inc.;
 Immunization Products Ltd. ST: California, Pennsylvania IN: MTC SU: JVN


DM-JL -- SD001 -- 0284 05/14/92 13:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 14, 1992
Words:338
Previous Article:MONOCLONAL MARKET TO EXPLODE WITH NEW CANCER, AUTOIMMUNE DRUGS
Next Article:TRANSCO ENERGY FILES FOR SALE OF NOTES
Topics:


Related Articles
RHONE-POULENC RORER AND BOEHRINGER MANNHEIM TO CO-DEVELOP THIRD GENERATION BISPHOSPHONATE.
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
WARNER-LAMBERT, RHONE-POULENC RORER AGREE TO CO-DEVELOP AND CO-PROMOTE ADVANCED QUINOLONE ANTIBACTERIAL IN U.S. AND CANADA
THE IMMUNE RESPONSE CORP., RHONE-POULENC RORER INC. ANNOUNCE PRELIMINARY EVALUATION OF HIV THERAPEUTIC VACCINE DOSE-RANGING CLINICAL TRIAL
DOSE-RANGING STUDY SHOWS HIV IMMUNOTHERAPEUTIC STIMULATES ANTIBODY AND CELLULAR RESPONSES
RHONE-POULENC RORER, IMMUNE RESPONSE CORPORATION ANNOUNCE A DEDICATED MANAGEMENT TEAM FOR JOINT VENTURE DEVELOPING SALK AIDS-IMMUNOTHERAPEUTIC
THE IMMUNE RESPONSE CORPORATION AND RHONE-POULENC RORER INC. COMMENCE ARBITRATION
RPR'S DERMIK DIVISION TO SET UP JOINT VENTURE IN CHINA
THE IMMUNE RESPONSE CORPORATION REGAINS ALL RIGHTS TO HIV IMMUNOTHERAPEUTIC FROM RHONE-POULENC RORER INC.
THE IMMUNE RESPONSE CORPORATION ANNOUNCES FIRST QUARTER 1995 FINANCIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters